{"disease":{"id":"high-risk-prostate-cancer","name":"high risk prostate cancer"},"drugs":{"marketed":[{"drug_id":"abiraterone","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (mHSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"chembl-chembl254328","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (CSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03340272","title":"PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT05406999","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT07455097","title":"COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT05009290","title":"A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":391,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT07189598","title":"Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":390,"lead_sponsor_name":"Center Eugene Marquis","has_results":false},{"nct_id":"NCT07450599","title":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07357259","title":"Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05303558","title":"A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Johnson & Johnson International (Singapore) Pte. Ltd.","has_results":false},{"nct_id":"NCT03362359","title":"Ga-68-PSMA-11 in High-risk Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT06636682","title":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Cellvax Therapeutics Inc","has_results":false},{"nct_id":"NCT03537391","title":"Novel Imaging in Staging of Primary Prostate Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Turku University Hospital","has_results":false},{"nct_id":"NCT04869371","title":"Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Hongqian Guo","has_results":false},{"nct_id":"NCT06555796","title":"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07054346","title":"Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Thomas Hope","has_results":false},{"nct_id":"NCT07027124","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT04236752","title":"Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca","phase":"NA","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT06384222","title":"Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Ivan de Kouchkovsky, MD","has_results":false},{"nct_id":"NCT05593497","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07208240","title":"Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT06765954","title":"Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT06765902","title":"Immunotherapy Before and After Surgery","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT01695473","title":"Neoadjuvant BKM120 in High-risk Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Won Kim","has_results":true},{"nct_id":"NCT05437679","title":"Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System","phase":"","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Angle plc","has_results":false},{"nct_id":"NCT05076851","title":"Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":2,"lead_sponsor_name":"Hongqian Guo","has_results":false},{"nct_id":"NCT06528210","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}